Riley Rachel S, Day Emily S
Department of Biomedical Engineering, University of Delaware, Newark, DE, USA.
Helen F. Graham Cancer Center & Research Institute, Newark, DE, USA.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Jul;9(4). doi: 10.1002/wnan.1449. Epub 2017 Feb 3.
Photothermal therapy (PTT), in which nanoparticles embedded within tumors generate heat in response to exogenously applied laser light, has been well documented as an independent strategy for highly selective cancer treatment. Gold-based nanoparticles are the main mediators of PTT because they offer: (1) biocompatibility, (2) small diameters that enable tumor penetration upon systemic delivery, (3) simple gold-thiol bioconjugation chemistry for the attachment of desired molecules, (4) efficient light-to-heat conversion, and (5) the ability to be tuned to absorb near-infrared light, which penetrates tissue more deeply than other wavelengths of light. In addition to acting as a standalone therapy, gold nanoparticle-mediated PTT has recently been evaluated in combination with other therapies, such as chemotherapy, gene regulation, and immunotherapy, for enhanced anti-tumor effects. When delivered independently, the therapeutic success of molecular agents is hindered by premature degradation, insufficient tumor delivery, and off-target toxicity. PTT can overcome these limitations by enhancing tumor- or cell-specific delivery of these agents or by sensitizing cancer cells to these additional therapies. All together, these benefits can enhance the therapeutic success of both PTT and the secondary treatment while lowering the required doses of the individual agents, leading to fewer off-target effects. Given the benefits of combining gold nanoparticle-mediated PTT with other treatment strategies, many exciting opportunities for multimodal cancer treatment are emerging that will ultimately lead to improved patient outcomes. WIREs Nanomed Nanobiotechnol 2017, 9:e1449. doi: 10.1002/wnan.1449 For further resources related to this article, please visit the WIREs website.
光热疗法(PTT)是一种通过肿瘤内嵌入的纳米颗粒对外源施加的激光产生热响应的疗法,作为一种高度选择性癌症治疗的独立策略,已有充分的文献记载。基于金的纳米颗粒是光热疗法的主要介质,因为它们具有以下特性:(1)生物相容性;(2)直径小,能够在全身给药后穿透肿瘤;(3)简单的金-硫醇生物共轭化学,用于连接所需分子;(4)高效的光热转换;(5)能够被调谐以吸收近红外光,近红外光比其他波长的光更能深入穿透组织。除了作为一种独立的疗法外,金纳米颗粒介导的光热疗法最近还被评估与其他疗法联合使用,如化疗、基因调控和免疫疗法,以增强抗肿瘤效果。当单独给药时,分子药物的治疗成功率会受到过早降解、肿瘤给药不足和脱靶毒性的阻碍。光热疗法可以通过增强这些药物的肿瘤或细胞特异性递送,或通过使癌细胞对这些额外疗法敏感来克服这些限制。总之,这些益处可以提高光热疗法和辅助治疗的治疗成功率,同时降低单个药物所需的剂量,从而减少脱靶效应。鉴于将金纳米颗粒介导的光热疗法与其他治疗策略相结合的益处,多模态癌症治疗正涌现出许多令人兴奋的机会,最终将改善患者的治疗效果。《WIREs纳米医学与纳米生物技术》2017年,9:e1449。doi:10.1002/wnan.1449 有关本文的更多资源,请访问WIREs网站。